Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Defining Subgroups of Small-Cell Lung Cancer

Defining Subgroups of Small-Cell Lung Cancer EDITORIAL Afshin Dowlati, MD, and Gary Wildey, PhD mall-cell lung cancer (SCLC) is a disease for which there has been no advance in sys- Stemic therapy for the past 30 years. In the background of this sobering data are many attempts to find targeted therapy that can have a real impact on patient outcome. These attempts may have failed largely because of our inability to identify subgroups of SCLC patients who have an appropriate predictive biomarker for response. Thus, in this setting, investigators are attempting to define, similar to non–small-cell lung cancer (NSCLC), subgroups of SCLC which behave differently. This represents a departure from what has traditionally been viewed as a homogeneous disease. An obvious subgroup, representing approximately 1% of all SCLC, are patients with so-called “peripheral SCLC” which pres- ent with a solitary pulmonary nodule and whom are candidates for surgery. Most genomic 3,4 data published to date have focused on this group, which has a very different clinical XXX course than the classic SCLC we observe in everyday clinical practice. Another subgroup is the so-called “combined SCLC,” previously called “mixed SCLC,” which has histological features of both SCLC and NSCLC and may also behave differently. This entity http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Journal of Thoracic Oncology Wolters Kluwer Health

Defining Subgroups of Small-Cell Lung Cancer

Wildey, Gary
Journal of Thoracic Oncology , Volume 9 (6) – Jun 1, 2014
Download PDF
2 pages

Loading next page...
 
/lp/wolters-kluwer-health/defining-subgroups-of-small-cell-lung-cancer-gUt02yZgXR

References (11)

Copyright
Copyright © 2014 by the International Association for the Study of Lung Cancer
ISSN
1556-0864
DOI
10.1097/JTO.0000000000000176
pmid
24828659
Publisher site
See Article on Publisher Site

Abstract

EDITORIAL Afshin Dowlati, MD, and Gary Wildey, PhD mall-cell lung cancer (SCLC) is a disease for which there has been no advance in sys- Stemic therapy for the past 30 years. In the background of this sobering data are many attempts to find targeted therapy that can have a real impact on patient outcome. These attempts may have failed largely because of our inability to identify subgroups of SCLC patients who have an appropriate predictive biomarker for response. Thus, in this setting, investigators are attempting to define, similar to non–small-cell lung cancer (NSCLC), subgroups of SCLC which behave differently. This represents a departure from what has traditionally been viewed as a homogeneous disease. An obvious subgroup, representing approximately 1% of all SCLC, are patients with so-called “peripheral SCLC” which pres- ent with a solitary pulmonary nodule and whom are candidates for surgery. Most genomic 3,4 data published to date have focused on this group, which has a very different clinical XXX course than the classic SCLC we observe in everyday clinical practice. Another subgroup is the so-called “combined SCLC,” previously called “mixed SCLC,” which has histological features of both SCLC and NSCLC and may also behave differently. This entity

Journal

Journal of Thoracic Oncology – Wolters Kluwer Health

Published: Jun 1, 2014

There are no references for this article.